Jessica Walters

FDA feedback for CYC-126: anesthetic therapy with live EEG guidance aims to deliver precise relief for treatment-resistant depression.

IV DMT psychedelic SPL026 reduces major depression in phase 2a.

FDA reviews INmune Bio’s biomarker-enriched Phase 2b/3 plan for XPro1595.

Brief interpersonal therapy in pregnancy sharply lowers depression and postpartum relapse for a year—offering clinicians a fast, safe option.

New research highlights psilocybin's potential in treating treatment-resistant OCD, while cannabinoids show little evidence of efficacy.

Review the latest in sports psychiatry before the 2026 winter Olympics.

Cognition extends zervimesine expanded access for Lewy body dementia, adding months of dosing and easier local monitoring.

Preclinical mGlu7 negative allosteric modulator ADX71743 disrupts fear-memory reconsolidation.

Discover insights from Lauren Kenworthy, PhD on treating comorbid ADHD and autism.

Neurocrine Biosciences launches a phase 2 trial for NBI-1065890.

LPCN 1154 shows promise as a rapid, at-home treatment for postpartum depression, with favorable safety results in ongoing phase 3 trials.

Researchers discuss precision medicine's potential to enhance opioid use disorder treatment.

Review the misperceptions patients and clinicians may have about ADHD diagnosis and treatment.

Experts discuss the complex relationship between ADHD treatment and substance use disorder.

Clinicians explore the complex relationship between ADHD medication and pregnancy, emphasizing individualized risk assessments for optimal maternal and child health.

A groundbreaking online ADHD assessment shows 78% agreement with clinician evaluations, enhancing access to mental health care for adults.

Explore key insights on ADHD treatment barriers and the long-term outcomes for adolescents diagnosed with the disorder.

New research reveals midlife ADHD patients exhibit early Alzheimer disease biomarkers.

Centanafadine demonstrates promising effects on ADHD symptoms, enhancing key neurotransmitters without increasing psychomotor activity, according to poster data.

A look at upcoming presentations at APSARD 2026, January 15-18.

NTX-253 enters phase 1 trials, exploring a novel approach to schizophrenia treatment with potential for improved safety and efficacy.

Cognition Therapeutics shares zervimesine's promising phase 2 results, showing safety and improved symptoms in dementia with Lewy bodies.

Clinicians can guide patients with bipolar disorder in setting flexible, achievable New Year’s goals, enhancing motivation and stability throughout mood fluctuations.

Discover groundbreaking findings on digital therapeutics and medications for schizophrenia and depression, showcasing safety and efficacy in recent studies.

Explore innovative treatments for schizophrenia, depression, and dementia, focusing on new medications and holistic care approaches for better patient outcomes.

Explore innovative approaches to mental health care, from jail diversion programs to addressing burnout in female physicians, enhancing patient outcomes.

Review the news from this year's Clinical Trials in Alzheimer's Disease conference.

See the variety of commentary, news, and happenings in artificial intelligence (AI) and psychiatry throughout this year.